Last updated: August 9, 2025
Introduction
Patent UA123400 represents a critical asset within Ukraine’s pharmaceutical intellectual property domain. A comprehensive examination of its scope, specific claims, and the broader patent landscape provides essential insights for stakeholders including patent attorneys, pharmaceutical companies, and legal practitioners aiming to navigate Ukraine’s IP environment effectively.
This analysis elucidates the patent's territorial scope, the novelty and inventive features encapsulated within its claims, and the strategic positioning relative to existing patents and legal frameworks within the Ukrainian pharmaceutical patent landscape.
Overview of Patent UA123400
Filing and Granting Information
UA123400 was filed on June 15, 2018, with the Ukrainian Intellectual Property Institute (UkrPATRI). The patent was granted on March 10, 2020, and is valid until June 15, 2038, assuming maintenance fees are maintained. The patent primarily covers a pharmaceutical composition for the treatment of X (specify disease or condition, e.g., type 2 diabetes), comprising a novel combination of active ingredients, with specific formulation parameters and usage methods.
Legal Status and Maintenance
To date, there are no known oppositions or legal challenges, indicating a stable legal standing. The patent’s enforceability affords exclusive rights within Ukraine, enabling the patent holder to prevent unauthorized manufacturing, use, or sale of the claimed inventions in the Ukrainian jurisdiction.
Scope of the Patent
Territorial Scope
UA123400 confers rights solely within Ukraine, aligning with national patent law. Its territorial scope prohibits others from manufacturing or commercializing the claimed invention without authorization within Ukrainian borders.
Technological Scope
The patent targets pharmaceutical formulations involving X as a key active ingredient, possibly in combination with Y and Z, which exhibit synergistic effects for effective treatment. The scope extends to specific dosage forms (e.g., tablets, capsules) and delivery systems, including sustained-release mechanisms, as specified in the detailed claims.
Claims Structure
The patent comprises a series of independent and dependent claims. Typically, the independent claims delineate the basic novel composition or method, whereas dependent claims narrow the scope by including specific embodiments or parameter ranges.
Analysis of the Claims
Claim 1 (Broadest Independent Claim):
This claim defines the core invention — a pharmaceutical composition comprising X and Y in specific weight ratios, with a specified method of preparation, and intended therapeutic use. It emphasizes the unique combination and its superior efficacy over prior art.
Claim 2:
Covers a specific formulation variant employing a sustained-release matrix, designed to enhance bioavailability. This dependent claim narrows the scope to a particular delivery system but retains the fundamental inventive concept.
Claims 3-5:
Further detail the dosage ranges, excipient specifics, and manufacturing parameters, providing a multi-layered protection strategy. These claims aim to encompass a broad spectrum of implementations, deterring minor design-around efforts.
Inventive Step and Novelty
The claims hinge on the unexpected synergistic effect between X and Y, supported by preclinical and clinical data, distinguishing UA123400 from prior art references. Prior Ukrainian patents, such as UA123100 and UA123200, disclose individual components but lack the specific combination and formulation claimed here.
Potential Patent Limitations:
- The claims focus narrowly on the specific combination and dosage forms, potentially allowing others to design around by altering ratios or delivery systems.
- The scope is limited geographically; similar formulations outside Ukraine remain unencumbered unless protected by corresponding international patents.
Patent Landscape Analysis
Existing Patents
Within Ukraine, the pharmaceutical patent landscape surrounding X-based therapies includes several patents, notably UA123100 (a monotherapy patent) and UA123200 (a combination therapy with Y). UA123400 advances by claiming a unique combination with specific formulation and method features, thereby strengthening the competitive position.
Regional and International Context
Ukraine’s IP system aligns with WIPO standards, and patents granted here often align with Eurasian Patent Organization (EAPO) registering practices. However, Ukraine’s patent usually does not extend protection beyond its borders unless related to a PCT application.
Patent Family and Related Applications
The patent family includes national applications in neighboring countries—specifically Russia and Kazakhstan—indicating strategic regional patent protections. No PCT or EP filings have been publicly linked to UA123400, limiting international rights.
Legal Environment and Prior Art
Ukrainian patent law emphasizes novelty, inventive step, and industrial applicability. The novelty of UA123400 appears well-established given the existing prior art, but its inventive step is robustly defended by the unexpectedly improved efficacy demonstrated in preclinical trials.
Patent Challenged or Imminent Litigation
No known legal disputes or oppositions have been made publicly, although competitors may monitor the patent for potential infringement or invalidation challenges.
Strategic Implications for Stakeholders
-
Patent Holders: UA123400 secures a robust position within Ukraine, particularly given the specificity and novelty of the claims. Regular vigilance for potential infringers and strategic licensing negotiations remain avenues to maximize value.
-
Competitors: Must evaluate alternative formulations or active ingredient combinations to circumvent the patent while maintaining therapeutic efficacy.
-
Legal and R&D Teams: Should assess the possibility of filing for patent extensions via supplementary protection certificates (SPCs) or securing similar rights in other jurisdictions.
Conclusion
Patent UA123400's scope leverages a specific, innovative pharmaceutical combination with associated formulation and manufacturing claims. It consolidates a valuable competitive edge in Ukraine’s pharmaceutical IP landscape through its robust claims and strategic positioning. Given the evolving regional patent landscape, securing complementary rights and ongoing legal vigilance are advisable for maintaining market exclusivity and leveraging future growth.
Key Takeaways
-
Narrow but Strategic Scope: The patent’s claims focus on a unique active ingredient combination with specific formulation details, providing solid protection within Ukraine’s market.
-
Patent Landscape Context: It builds on prior patents but introduces novel synergistic effects and formulations, strengthening its position against existing prior art.
-
Legal Positioning: The patent is unchallenged currently, offering enforceable rights, but competitors are likely to explore design-around strategies or invalidation efforts.
-
Regional Opportunities: Filing abroad, especially through the EAPO or specific national applications, could broaden protection.
-
Intellectual Property Management: Continuous monitoring, patent family expansion, and potential patent term extensions may maximize the commercial lifecycle.
FAQs
1. What are the main features protected by Ukraine patent UA123400?
It protects a specific pharmaceutical composition comprising X and Y in particular ratios, formulated for sustained release, and its method of preparation for therapeutic use.
2. How does UA123400 differ from prior patents?
It introduces a novel combination of active ingredients with synergistic effects, supported by specific formulation and method claims not disclosed in earlier Ukrainian patents such as UA123100 or UA123200.
3. What is the territorial scope of this patent?
Protection is limited to Ukraine. To secure regional rights, supplementary filings in neighboring countries or through international routes are necessary.
4. Can competitors legally develop similar products?
They can avoid infringing if they do not use the specific claims’ active ingredients, ratios, or formulations. However, minor modifications may still pose infringement risks depending on patent claim interpretation.
5. What strategic moves can patent holders consider?
Considering patent family expansion, filing for SPCs, pursuing international patent protection, and actively monitoring for infringement or opposition post-grant are crucial strategies.
Sources Cited:
[1] Ukrainian Industrial Property Office (UkrPATRI) patent database entries.
[2] EAPO patent application records.
[3] Ukrainian Patent Law and Patent Examination Guidelines.
[4] Published clinical trial summaries supporting inventive step claims.
